Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Japanese Journal of Ophthalmology · 2024-09 · 68 (5) · 531-537
DOI: 10.1007/s10384-024-01107-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, online erschienen am 20.08.2024. Verfasst von Hidetaka Matsumoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan. hide-m@gunma-u.ac.j…. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Intravitreal Injections, Visual Acuity. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate short-term outcomes of intravitreal injection of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). Study design Retrospective, interventional case series.
Methods
We retrospectively studied 35 eyes of 34 consecutive patients with nAMD, assessing best-corrected visual acuity (BCVA), foveal thickness (FT), and central choroidal thickness (CCT) before and 4 weeks after the initial intravitreal dose of aflibercept 8 mg. The rate of achieving a dry macula and the incidence of intraocular inflammation (IOI) at week 4 were also determined.
Results
BCVA showed significant improvement, with significant reductions in FT and CCT 4 weeks after the initial injection of aflibercept 8 mg (all P < 0.01), with a dry macula being achieved in 20 eyes (57.1%). However, 3 eyes (8.6%) developed non-infectious IOI associated with retinal vasculitis, an adverse event not reported previously. The IOI in these eyes was relatively mild and treated with a posterior subtenon injection of triamcinolone acetonide with or without betamethasone eye drops, resulting in amelioration of IOI without any visual loss.
Conclusions
Intravitreal aflibercept 8 mg appears to be effective for improving visual acuity and ameliorating exudative changes in eyes with nAMD. However, special attention should be given to the potential development of IOI associated with retinal vasculitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan. hide-m@gunma-u.ac.jp.
- Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
Zitieren
APA
Matsumoto, H., Hoshino, J., Numaga, S., Mimura, K., Asatori, Y., & Akiyama, H. (2024). Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 68(5), 531-537. https://doi.org/10.1007/s10384-024-01107-w
Vancouver
Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. 2024;68(5):531-537. doi:10.1007/s10384-024-01107-w
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Hidetaka and Hoshino, Junki and Numaga, Saki and Mimura, Kaori and Asatori, Yosuke and Akiyama, Hideo},
title = {Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration},
journal = {Japanese Journal of Ophthalmology},
year = {2024},
volume = {68},
number = {5},
pages = {531--537},
doi = {10.1007/s10384-024-01107-w}
}
EUVIMED